Brand and Other Names:Fludara, Oforta
- Classes: Antineoplastics, Antimetabolite
Dosing & Uses
Dosage Forms & Strengths
powder for injection
B-Cell Chronic Lymphocytic Leukemia
40 mg/sq.meter PO x5 days
- CrCl 30-70 mL/min: reduce by 20%
- CrCl <30 mL/min: IV not recommended; PO reduce 50%
Non-Hodgkin Lymphoma (Orphan)
Treatment and management of non-Hodgkin lymphoma
Orphan indication sponsor
- Berlex Laboratories, Inc; 15049 San Pablo Avenue, P.O. Box 4099; Richmond, CA 94804-0099
Monitor: CBC, chemistries, pulmonary function
Other Indications & Uses
Off-label: hairy cell leukemia, NHL, prolymphocytic leukemia, mycosis fungoides, Hodgkin's disease
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Objective weakness (65%)
Leukopenia (partly therapeutic)
Infection (44%-not necessarily drug-induced)
Visual disturbances (15%)
GI bleeding (13%)
Abdominal pain (10%)
Back pain (9%)
Flu like syndrome (5-9%)
Hearing Loss (2-6%)
Peripheral edema (7%)
Black Box Warnings
The drug should be administered under the supervision of an experienced cancer chemotherapy physician
Bone marrow suppression may occur. Fludarabine has been associated with severe neurologic effects, including blindness, coma when high doses were used in patients with acute leukemia. Agitation, coma, confusion, and seizures have been reported in patients treated at recommended doses for the treatment of chronic lymphocytic leukemia
If one or more cycles of treatment with fludarabine administered, autoimmune phenomena including acquired hemophilia, autoimmune thrombocytopenia/thrombocytopenic purpura, Evan syndrome, and hemolytic anemia may occur. Monitor patients closely for hemolysis
Fludarabine in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia is not recommended due to a high incidence of fatal pulmonary toxicity
Concomitant pentostatin: risk of fatal pulmonary toxicity
IV: severe renal impairment
Bone marrow depression, renal impairment, elderly
Allopurinol and hydration recommended for patients newly diagnosed with CLL or those at risk of tumor lysis syndrome
Very high doses (and rarely, normal doses) have caused irreversible or fatal neurotoxicity manifesting after 21-60 days
Risk of potentially fatal autoimmune hemolytic anemia
No efficacy in children
Pregnancy & Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, do not nurse
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Peak plasma time: 2 hr
Vd: 96-98 L/sq.meter
Protein bound: 19-29%
Clearance: 8.9 L/hr/sq.meter
Mechanism of Action
Fluorinated purine analog, inhibits DNA polymerase alpha
Y-site: acyclovir, amphotericin B, chlorpromazine, daunorubicin, ganciclovir, hydroxyzine, prochlorperazine
Y-site (partial list): allopurinol, ampicillin, bleomycin, carboplatin, most cephalosporins, cisplatin, dactinomycin, doxorubicin, fluconazole, hydromorphone, imipenem-cilastatin, lorazepam, MgSO4, metoclopramide, morphine SO4, KCl, NaHCO3, TMP-SMX, vancomycin, zidovudine
Reconstitute powder for inj with 2 mL SWI to result in a concentration of 25 mg/mL
Standard IV dilution: dose/100 mL D5W or NS
IV infusion over 30 min recommended by Mfr; has been given as continuous infusion or by rapid injection but risk of toxicity may be higher
Store intact vials under refrigeration
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs